This post was originally published on this site Melanoma patients who become resistant to immune checkpoint inhibitors may regain susceptibility to such treatments after receiving Targovax‘s immune activator ONCOS-102, early clinical trial findings suggest. The trial is testing a combination of ONCOS-102 and the immune checkpoint inhibitor Keytruda (pembrolizumab) in advanced or surgery-ineligible melanoma patients…

This post was originally published on this site Men with prostate cancer who undergo treatment with androgen deprivation therapy (ADT) — a form of hormone therapy that aims to slow disease progression by reducing the levels of male hormones — may be more likely to develop Alzheimer’s disease and dementia, a large database study reports.…

This post was originally published on this site Women with ovarian cancer who have a family history of breast or ovarian cancer, and are younger than 45 if breast cancer in a near relative makes up that history, are more likely to have inherited BRCA mutations and could benefit from a genetic test to see if they…

This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended that Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone be approved to treat adults with relapsed or refractory multiple myeloma in Europe. The therapy, collectively known as the…

This post was originally published on this site Anixa Biosciences, a leading company developing anti-cancer immunotherapies, is partnering with the Cleveland Clinic to advance a vaccine against triple-negative breast cancer (TNBC) to testing in humans. “We are pleased to be able to work with Anixa to advance this technology into human trials,” Cleveland Clinic researcher…

This post was originally published on this site Nearly $169,000 was raised to support the Leukemia & Lymphoma Society’s research, legislative advocacy, and patient support efforts by one of its chapter’s Man & Woman of the Year campaign. California residents Nancy Whitman and John Romley won the title for the Silicon Valley & Monterey Bay…

This post was originally published on this site A first-in-human Phase 1 clinical trial has been launched to assess the effects of NantKwest’s investigational PD-L1 t-haNK cell therapy in patients with locally advanced or metastatic solid cancers. The authorization to start the trial came after the U.S. Food and Drug Administration (FDA) completed a review…

This post was originally published on this site Minerva Biotechnologies will soon start the first human trials testing its investigational therapy huMNC2-CAR44, a CAR T-cell immunotherapy intended for breast cancer that has spread to other parts of the body. The announcement comes after the U.S. Food and Drug Administration (FDA) approved the company’s investigational new…

This post was originally published on this site Researchers from the University of Pittsburgh Medical Center (UPMC) have teamed up with Helomics — a subsidiary of Predictive Oncology — to explore the use of artificial intelligence as a way to improve the treatment decision process for ovarian cancer. Despite the advances made to improve diagnosis…

This post was originally published on this site To ultimately drive immunotherapy discoveries in a complex cancer, the Multiple Myeloma Research Foundation (MMRF) has launched a precision medicine research initiative. Called Immune Atlas, the pilot aims to establish a “gold standard” immune profiling platform for multiple myeloma research studies, and to produce the kind of…

This post was originally published on this site Triumvira Immunulogics is launching a Phase 1/2 clinical trial to test its  T-cell therapy candidate, TAC01-CD19, in patients with B-cell lymphoma across the U.S. and Canada, the company announced. The TACTIC-19 trial (NCT03880279), set to begin in a few months, comes after the U.S Food and Drug…

This post was originally published on this site PyL, a new imaging agent for positron emission topography (PET) scans, can accurately detect prostate cancer lesions outside the prostate, whether in nearby lymph nodes or in distant locations, clinical trial data show. The tracer — developed by Progenics — is a second generation fluorine-labeled small molecule that…